The National Institute for Health and Care Excellence (NICE) is producing guidance on using clopidogrel genotype testing after ischaemic stroke or transient ischaemic attack in the NHS in England. The diagnostics advisory committee has considered the evidence and the views of clinical and patient experts.

This document has been prepared for public consultation. It summarises the evidence and views that have been considered, and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public. This document should be read along with the evidence (the external assessment report and the external assessment report erratum).

The advisory committee is interested in receiving comments on the following:

  • Has all of the relevant evidence been taken into account?
  • Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?
  • Are the recommendations sound, and a suitable basis for guidance to the NHS?

You can now comment on the diagnostics consultation document.  

 It summarises the evidence and views that have been considered and sets out the recommendations made by the committee. NICE invites comments from registered stakeholders, healthcare professionals and the public.  

How to comment 

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. 

We have a new way of making comments on this consultation. You must make your comments directly onto the online version of the consultation document. When you go into the document you will find instructions on how to use the new commenting software.  You can also review and edit your comments before you submit them. 

You can download a PDF version of the consultation document, but you can only make comments on the online version. 

Equality issues

NICE is committed to promoting equality of opportunity, eliminating unlawful discrimination and fostering good relations between people with particular protected characteristics and others. Please let us know if you think that the recommendations may need changing to meet these aims. In particular, please tell us if the recommendations:

  • could have a different effect on people protected by the equality legislation than on the wider population, for example by making it more difficult in practice for a specific group to access the technology
  • could have any adverse effect on people with a particular disability or disabilities.

Please provide any relevant information or data you have about such effects and how they could be avoided or reduced.

Note that this document is not NICE's final guidance on clopidogrel genotype testing. The recommendations in section 1 may change after consultation.

A further committee discussion will be held if significant issues are raised during consultation. The committee will then prepare its final recommendations, which will be the basis for NICE’s guidance on the use of the technology in the NHS in England. The evaluation will then proceed to resolution.

For further details, see NICE health technology evaluations: the manual.

If you have any problems, contact 

Key dates:

Closing date for comments: 26 April 2024